License Fees, Potential Future Milestone Payments Receivable

No definition available.

Name:	apri_LicenseFeesPotentialFutureMilestonePaymentsReceivable
Namespace Prefix:	apri_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research And Development, Number Of Phase 3 Clinical Efficacy Trials Required

+ References

No definition available.

+ Details

Name:	apri_ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired
Namespace Prefix:	apri_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Rate, Potential Receivable On Sales Of Product, Percentage

+ References

No definition available.

+ Details

Name:	apri_RoyaltyRatePotentialReceivableOnSalesOfProductPercentage
Namespace Prefix:	apri_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of other research and development expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_ProductOrServiceAxis=apri_VitarosMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=apri_AllerganformerlyWarnerChilcottMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Allergan In-Licensing Agreement - Narrative (Q3) (Details) $ in Millions	1 Months Ended
	Apr. 30, 2018 Clinicaltrial	Sep. 30, 2017 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2018 USD ($)	Dec. 31, 2017 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of Phase 3 clinical efficacy trials required \| Clinicaltrial	2
Vitaros
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of Phase 3 clinical efficacy trials required \| Clinicaltrial	2
Allergan \| Vitaros
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to Allergan, research and development \| $		$ 1.5	$ 1.0
License fees, potential future milestone payments receivable \| $				$ 25.0	$ 25.0
Allergan \| Vitaros \| Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty rate, potential receivable on future product sales (percent)				10.00%
Allergan \| Vitaros \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty rate, potential receivable on future product sales (percent)				20.00%